Clinical Trials | October 13, 2025
Roche to present latest cancer care data at ESMO 2025
Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant
Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant
The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases
AstraZeneca to invest $50bn in manufacturing and R&D to support domestic sourcing
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
The Court dismissed Swiss drugmaker Roche’s plea for interim injunction
Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at 36 months in Phase I trial participants
The new line features advanced isolator technology to deliver enhanced sterility assurance, throughput and operational precision
The initiative successfully demonstrates that used medical plastic packaging can be recycled and transformed back into new, contact-sensitive medical packaging
Subscribe To Our Newsletter & Stay Updated
